United States: FDA To Step Up Enforcement Of Homeopathic Medicine

Homeopathic medicine has long occupied a niche in American culture. Since 1988, with the issuance of the Compliance Policy Guide, § 400.400, "Conditions Under Which Homeopathic Drugs May be Marketed," the FDA has had a relatively hands-off relationship with homeopathic products. However, this is likely to change as the agency shifts to a risk-based enforcement approach under new FDA Draft Guidance issued in December 2017. 

As a general matter, homeopathic medicine is based on two core concepts:

  1. Substances that cause symptoms in a healthy person can be used in a diluted form to treat the same symptoms and illnesses in sick people. This is also known as the principle of "like cures like."
  2. The more diluted a substance becomes, the more potent it becomes. This is also known as the "law of infinitesimals."

Practitioners of homeopathic medicine claim that taking a given compound and diluting it with water in increasing amounts results in a solution with a commensurate increase in therapeutic efficacy. That is, the lower the amount of symptom-causing compound in a homeopathic medicine, the greater the efficacy. Historically, practitioners have found therapeutic uses by dosing healthy people with symptom-inducing compounds, diluting the compound in water and giving the resulting compounds to unhealthy people presenting the same symptoms.

Homeopathy was recognized when the FDA was formed in 1938 with the passing of the Federal Food, Drugs and Cosmetics Act (FDCA). See 21 U.S.C. § 201(g)(1). When the FDCA was drafted, an article recognized in the Homeopathic Pharmacopoeia of the United States (HPUS) was considered a drug. However, the FDA's enforcement of the FDCA as to homeopathic companies has been inconsistent. Since 1988, the FDA has applied internal Compliance Policy Guide, CPG § 400.400 when regulating the homeopathic industry. Essentially, CPG §400.400 stated that the FDA will focus its enforcement efforts on those entities and products that did not comply with the relatively minimal requirements of the CPG.

Homeopathic medicine has in recent years expanded to include other niche industries that claim their products can cure diseases, decrease symptoms, or relieve discomfort. The homeopathic medicine industry has grown to a $3 billion per year industry in the U.S. and has seen an increase in products making claims of dubious accuracy.

With the FDA's new Draft Guidance entitled "Drug Products Labeled as Homeopathic: Guidance for FDA Staff and Industry," the FDA's enforcement policy is changing entirely and CPG § 400.400 from 1988 is being rescinded.

In releasing the new draft guidance, FDA Commissioner Scott Gottlieb stated:

"In recent years, we've seen a large uptick in products labeled as homeopathic that are being marketed for a wide array of diseases and conditions, from the common cold to cancer. In many cases, people may be placing their trust and money in therapies that may bring little to no benefit in combating serious ailments, or worse – that may cause significant and even irreparable harm because the products are poorly manufactured, or contain active ingredients that aren't adequately tested or disclosed to patients. Our approach to regulating homeopathic drugs must evolve to reflect the current complexity of the market, by taking a more risk-based approach to enforcement. We respect that some individuals want to use alternative treatments, but the FDA has a responsibility to protect the public from products that may not deliver any benefit and have the potential to cause harm."

Homeopathic drugs are drugs once more

CPG § 400.400 stood for, among other things, an exception to the general rules surrounding drug products in the U.S. and applied relaxed requirements to homeopathic products. However, the FDA's new guidance re-establishes the FDCA's status quo wherein homeopathic products  are once again drugs as defined in 21 U.S.C. § 321(g) and 21 U.S.C. § 262(a) and, as such, subject to the same pre-market application and review processes applicable to drugs, biologics and over-the-counter products. This applies to product labeling and marketing requirements, as well as current good manufacturing practices and other regulatory requirements.

Now, instead of waiving many regulatory requirements applicable to drugs, the FDA is applying a risk-based enforcement approach, focusing the agency's efforts on products that pose the highest risk to patients:

  • Products with reported safety concerns. These include products that are the subject of MedWatch reports or other reports received by the FDA related to safety or efficacy, adverse events, or other safety issues.
  • Products containing high-risk ingredients. These products have ingredients the FDA recognizes as associated with safety concerns. These include:

    • Infectious agents
    • Controlled substances
    • Ingredients that can interact and cause safety issues
    • Ingredients that pose potential toxic effects in a given concentration found in the product
  • Products that use dangerous or risky routes of administration. Products that use administration methods other than oral and topical applications, such as injections or ophthalmic application. 
  • Products that claim to treat serious and/or life threatening diseases of conditions or that target vulnerable populations. These products may put patients at risk by causing patients to delay or discontinue proven safe and effective treatment methods.
  • Products found to be adulterated under FDA regulations.

Implementation, enforcement and timelines are unknown

In the Draft Guidance and press release accompanying it, the FDA did not provide any kind of timeline for these enforcement activities. However, the agency explicitly stated that it will not be providing companies with advanced warning of enforcement actions. As such, it will be difficult to determine where a given product or company falls within the FDA's enforcement priorities. However, members of the homeopathic industry should immediately review current product offerings and related marketing to identify any relation to the five groups of high-risk products described by the FDA above.

If you or your company market homeopathic products and have any questions about this enforcement initiative or the Draft Guidance, or are interested in reviewing your current product offerings, please feel free to reach out to one of our team members for assistance. We have a team of attorneys experienced working with the FDA, FDA enforcement actions and product reviews that can help you understand where your risks may lie.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions